Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151788 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.
A Phase 2 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 796
- Enrollment target
NCT00151788 is a Phase 2 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 796 participants.
The verdict
NCT00151788, a Phase 2 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 796 participants
- Enrollment target
Study Summary
The effects of pactimibe versus placebo on the progression of atherosclerosis in the carotid arteries will be assessed using standard ultrasound techniques.
Interventions
- DRUG Pactimibe sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 796 participants |
| Start Date | 2004-02 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151788
The ClinicalTrials.gov registry entry for NCT00151788 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 796 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pactimibe sulfate is the first listed.
NCT00151788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151788 about?
NCT00151788 is a clinical study titled "Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.". The effects of pactimibe versus placebo on the progression of atherosclerosis in the carotid arteries will be assessed using standard ultrasound techniques.
What is the current status of trial NCT00151788?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 796 participants. The study started on 2004-02. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00151788?
The interventions under investigation include: Pactimibe sulfate (DRUG).
Who is sponsoring clinical trial NCT00151788?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.